CIAM
ANTX icon

Caitong International Asset Management’s AN2 Therapeutics ANTX Stock Holding History

Caitong International Asset Management’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.33K Sell
274
-2,326
-89% -$10K ﹤0.01% 1480
2026
Q1 		$8.89K Buy
+2,600
New +$5.37K ﹤0.01% 1092

Other funds holding ANTX

VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Caitong International Asset Management's ANTX Position: Q2 2026 in Review

Caitong International Asset Management reduced its AN2 Therapeutics (ANTX) stake by 89% in Q2 2026, selling an estimated $10K and leaving 274 shares worth $1.33K. The position accounts for ﹤0.01% of the portfolio, ranked #1480.

Caitong International Asset Management first reported a position in ANTX in Q1 2026 and has held it in 2 quarters since. The position peaked at $8.89K in Q1 2026. 66 funds tracked by Wall St. Rank hold ANTX as of Q2 2026.

  • Caitong International Asset Management held 274 shares of AN2 Therapeutics worth $1.33K as of Q2 2026.
  • Caitong International Asset Management sold 2,326 AN2 Therapeutics shares in Q2 2026, an estimated $10K.
  • AN2 Therapeutics made up ﹤0.01% of Caitong International Asset Management's portfolio in Q2 2026, its #1480 holding.
  • Caitong International Asset Management first reported a position in AN2 Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Caitong International Asset Management's AN2 Therapeutics position peaked at $8.89K in Q1 2026.
  • 66 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.